Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) announces a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion. Exact Sciences focuses on the early detection of cancer and supporting personalized treatments. Exact Sciences’ comprehensive product offerings support patients and their healthcare providers before, during and after a cancer diagnosis.
Read the full article: Abbott to Acquire Exact Sciences, a Leader in Large and Fast-Growing Cancer Screening and Precision Oncology Diagnostics Segments //
Source: https://www.prnewswire.com/news-releases/abbott-to-acquire-exact-sciences-a-leader-in-large-and-fast-growing-cancer-screening-and-precision-oncology-diagnostics-segments-302621643.html